Biography
Dr. Kurzrock is a board-certified medical oncologist and a renowned expert in precision medicine. She is known for developing one of the largest and best known Phase I clinical trial programs in the United States while at MD Anderson Cancer Center in Texas. Dr. Kurzrock established the UCSD’s Center for Personalized Cancer Therapy at the Moores Cancer Center. The center focuses on genomically-driven therapy as well as precision immunotherapy, especially in rare cancers. Dr. Kurzrock is a global leader in personalized medicine, bringing the first transcriptomic study to the clinic in an international setting spanning five countries (WINTHER), as well as the first study of individually customized combination therapy (IPREDICT). Dr. Kurzrock received her MD from the University of Toronto, Canada. She has over 800 PubMed publications, an H-index of 122, has been named to the lists of most highly cited scientists in the world and the 25 world leaders in precision medicine, and she has a uniquely strong record of competitive funding with more than 100 million dollars in lifetime funding.

Biography
Dr. Kurzrock is a board-certified medical oncologist and a renowned expert in precision medicine. She is known for developing one of the largest and best known Phase I clinical trial programs in the United States while at MD Anderson Cancer Center in Texas. Dr. Kurzrock established the UCSD’s Center for Personalized Cancer Therapy at the Moores Cancer Center. The center focuses on genomically-driven therapy as well as precision immunotherapy, especially in rare cancers. Dr. Kurzrock is a global leader in personalized medicine, bringing the first transcriptomic study to the clinic in an international setting spanning five countries (WINTHER), as well as the first study of individually customized combination therapy (IPREDICT). Dr. Kurzrock received her MD from the University of Toronto, Canada. She has over 800 PubMed publications, an H-index of 122, has been named to the lists of most highly cited scientists in the world and the 25 world leaders in precision medicine, and she has a uniquely strong record of competitive funding with more than 100 million dollars in lifetime funding.

Biography
Dr. Kurzrock is a boardcertified medical oncologist and a renowned expert in precision medicine. She developed one of the worlds largest Phase I clinical trial programs while at MD Anderson Cancer Center. Dr. Kurzrock also founded the UCSDs Center for Personalized Cancer Therapy, focusing on genomicallydriven therapy as well as precision immunotherapy, especially in rare cancers. Dr. Kurzrock brought the first transcriptomic study to the clinic in an international setting spanning five countries (WINTHER), as well as the first Nof1 study of individually customized combination therapy (IPREDICT). Dr. Kurzrock received her MD from the University of Toronto, Canada. She has 900 PubMed publications, an Hindex of 140, has been named to the lists of most highly cited scientists in the world. She has a uniquely strong record of competitive funding with 100 million dollars in lifetime funding, and has overseen early development of multiple drugs that are now FDA approved.

Biography
Charles M. Perou, PhD is currently the Co-Director of the Computational Medicine Program, Faculty Director of the Lineberger Comprehensive Cancer Center (LCCC) Bioinformatics Group, and Co-Leader of the LCCC Breast Cancer Research Program at UNC. He is also a member of the ALLIANCE Breast Committee, and the Executive Steering Committee Member of the Translational Breast Cancer Research Consortium (TBCRC). Dr. Perou co-founded 3 biotechnology companies (Bioclassifier, GeneCentric Therapeutics, and Reveal Genomics), which are broadly focused on using genomic assays coupled to novel therapeutics to make improvements for personalized patient care and ultimately to improve cancer patient survival outcomes. His training history includes a Bachelor's degree in Biology from Bates College, a PhD in Experimental Pathology from the University of Utah, and postdoctoral work in the laboratory of David Botstein (then at Stanford University). He won a number of awards including the European Institute of Oncology Breast Cancer Therapy Award, the Jill Rose Award for Distinguished Biomedical Research from BCRF, the Brinker Award for Scientific Distinction from Komen, the Distinguished Scientist Award from the Association of American Cancer Institutes, and most recently been elected as a Fellow of the AACR (FAACR). He authored more than 450 peer reviewed articles, and has been named an inventor on multiple USA and European patents. Lastly, He has been named a Thomson Reuters Most Highly Cited Researcher in 2014-2022, where his work has received more than 240,000 total citations according to Google Scholar.

Biography
Bruce Quinn is a recognized expert on Medicare policy for innovative technologies. He has helped both large and small companies plan product development and market entry strategies and resolve emerging reimbursement issues efficiently. His policy blog, Discoveries in Health Policy, is distributed to over 500 health policy experts each week.

Biography
Catriona Jamieson is a leading physician scientist who has specialized in myeloproliferative neoplasms (MPNs) and leukemia. She discovered missplicing, RNA hyperediting, and splice isoform switching as mechanisms governing human cancer stem cell maintenance in selective niches. These discoveries have helped to shed light on the underlying mechanisms of cancer and have opened up new avenues for targeted therapies. Dr. Jamieson's contributions to the field of precision medicine include her pivotal role in the rescue and development of the JAK inhibitor fedratinib for the treatment of myelofibrosis. Additionally, she is known for her unwavering dedication to advancing innovative therapies and her outstanding leadership as the director of the Sanford Stem Cell Institute at UCSD and as a co-founder of Impact Biosciences and Aspera Biomedicines.

Biography
Ben George, MD is the William F. Staff Endowed Chair and Associate Professor of Medicine in the Division of Hematology and Oncology at the Medical College of Wisconsin. He also serves as the Medical Director of the Clinical Trials Office at the Froedtert and Medical College of Wisconsin Clinical Cancer Center. Dr. George is a Gastrointestinal Medical Oncologist with a clinical and research focus on Pancreatic Cancer. He has been a faculty member at MCW since 2011.

Biography
Eytan Ruppin has served as a professor of Computer Science Medicine since 1995, conducting computational multidisciplinary research spanning computational neuroscience, natural language processing, machine learning and systems biology. In 2014, he joined the University of Maryland as director of its Center for Cioinformatics and Computational Biology (CBCB). In 2018, he moved to the NCI where he founded and is chief of its Cancer Data Science Lab (CDSL). His research is focused on developing new computational approaches for advancing transcriptomics-based precision oncology. Eytan is a member of the editorial board of Molecular Systems Biology, a fellow of the International Society for Computational Biology (ISCB), a recipient of the NCI Director award and the Delano awards and is a co-founder of a few precision medicine startup companies.

Biography
I am a boardcertified medical oncologist specializing in the treatment of patients with gastrointestinal (GI) cancers, particularly colorectal cancer (CRC), appendix cancer, and cholangiocarcinoma. My research is focused on the development of novel systemic and regional therapies, including approaches based on tumor genomics, with the goal of improving outcomes while minimizing treatmentrelated toxicities. I am the founder and codirector of the Center for Young Onset Colorectal and Gastrointestinal Cancer. This clinic the first of its kind in the world is dedicated solely to the specific needs of people under 50 who have CRC or other GI cancers.

Biography
Catriona Jamieson is a leading physician scientist who has specialized in myeloproliferative neoplasms (MPNs) and leukemia. She discovered missplicing, RNA hyperediting, and splice isoform switching as mechanisms governing human cancer stem cell maintenance in selective niches. These discoveries have helped to shed light on the underlying mechanisms of cancer and have opened up new avenues for targeted therapies. Dr. Jamieson's contributions to the field of precision medicine include her pivotal role in the rescue and development of the JAK inhibitor fedratinib for the treatment of myelofibrosis. Additionally, she is known for her unwavering dedication to advancing innovative therapies and her outstanding leadership as the director of the Sanford Stem Cell Institute at UCSD and as a cofounder of Impact Biosciences and Aspera Biomedicines.

Biography
Dr. Sandhya Girish is the Vice President of Clinical Pharmacology Sciences at Gilead Sciences, Inc. Dr. Girish provides strategic and scientific leadership for clinical pharmacology, pharmacometrics and bioanalytical strategies for NMEs spanning both early and late stages of development. Her department is actively involved in a variety of pediatric and adult RD programs across virology, oncology, and inflammation therapeutics areas and is responsible for integrated clinical pharmacology, and MS strategies, including applying MIDD approaches where appropriate. Sandhya has organized technical sessions, workshops and roundtable discussions on therapeuticprotein drug interactions, ADCsTDCs, Novel Combinations, Organ Impairment, FIH dosing etc. With support from her team Dr. Girish has successfully led and supported numerous submissions, including but not limited to Herceptin, Perjeta, Kadcyla, TECENTRIQ, POLIVY, Trodelvy, Sunlenca, etc. Sandhya is passionate about combining insights from clinical trials with data from virtual clinical trials, RWD, AIML to accelerate drug development.

Biography
Michael Milburn has over 20 years of executive leadership experience in drug and diagnostic companies including GSK, Plexxikon, Sirtris Pharmaceuticals, and Metablolon. A biotechnology innovator, he has published over 150 scientific articles and is an expert in the development and commercialization of drug and diagnostic products. He started his career in structurebased drug discovery and published the first scientific articles on the crystal structures of p21 ras proteins in the active and inactive state. He developed the first structurebased fragment screening technology and chemistry and published the first scientific articles on this drug discovery methodology. At GeneCentric, Michael leads the effort to bring RNA based diagnostics to the forefront of precision medicine and the next generation of companion diagnostics.

Talk
Advancing Precision Medicine with Novel RNA Companion Diagnostics
GeneCentric develops and commercializes novel RNAbased companion diagnostics to augment shortcomings in more traditional diagnostic testing such as DNA alterations or IHC. While DNA variants have been valuable in precision medicine, they only reflect potential oncogenic activation. In contrast, RNA diagnostics can be derived to reflect actual oncogenic activity and therefore more predictive of therapy.

Biography

Biography
Maggie joined Labcorp in 2022 through our acquisition of Personal Genome Diagnostics Inc. (PGDx)where she was Head of Marketing and Commercial Strategy. Since joining Labcorp, Maggie has served asthe Head of Oncology marketing with responsibility for leading our gotomarket efforts for Oncologydrug development, Diagnostics as well as Cell and Gene Therapy. As a veteran of the genomics industry, Maggie is passionate about empowering teams to deliver innovative, highly differentiated solutions to market that can improve the human condition. Prior to PGDx, Maggie served as Head, Oncology Product Management and Strategy at Invitae (NVTA), having joined Invitae through the acquisition of ArcherDX, where she served as Executive Vice President, Commercial Operations. Maggie also held sales and marketing leadership roles supporting academic, government, pharma and clinical markets for Agilent Technologies (A), Advanced Cell Diagnostics, Cogenics, Incyte Genomics (INCY) and Stratagene.

Biography
Hope S. Rugo, is a Professor of Medicine in the Division of HematologyOncology at the University of California, San Francisco (UCSF). She is Director of Breast Oncology and Clinical Trials Education at UCSF's Helen Diller Family Comprehensive Cancer Center.Dr. Rugo is an internationally recognized expert in breast cancer. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating tumor DNA as a marker of response and resistance to therapy, neoadjuvant therapy, and safetysupportive care.She is a principal investigator of multiple clinical trials and has published widely in medical journals. Dr. Rugo also plays an active role in the Alliance for Clinical Trials in Oncology, the Translational Breast Cancer Research Consortium, ASCO, MASCC, and international guideline committees including NCCN. Dr. Rugo is dedicated to education and mentorship, providing guidance to medical students, residents, and fellows at UCSF and beyond.

Biography
Dr. Adrian Lee is the Pittsburgh Foundation Chair and Director of the Institute for Precision Medicine (IPM), a joint effort by UPMC and the University of Pittsburgh to move biomedical research into personalized wellbeing and clinical care. He is also Professor of Pharmacology Chemical Biology and Human Genetics at UPMC Hillman Cancer Center. Dr. Lee received B.Sc. and Ph.D. degrees in England, and came to San Antonio, Texas for his postdoctoral studies. He was subsequently recruited to Baylor College of Medicine and to the University of Pittsburgh in 2010. The goal of Dr. Lees research laboratory is to translate basic cell and molecular research findings into the understanding and treatment of breast cancer. Dr Lee has published over 180 peer reviewed research articles. His laboratory is supported by funding from the NIH, Department of Defense, Susan G. Komen for the Cure, Breast Cancer Research Foundation, and other sources.

Biography
Dr. Grammer is an internationally recognized scientist and successful entrepreneur, having founded and managed AMPEL successfully for over 5 years. Dr. Grammer was elected to the class of 2021 for SIBF (Society of International Business Fellows), an organization of 1,400 individuals in 45 countries worldwide. She was also awarded a Virginia SBIG grant for AMPEL's first investment round. She is a second term board member of Virginia Bio.Before cofounding AMPEL in 2013, Dr. Grammer spent over 20+ years in genomics and managed more than 15 National Institute of Health (NIH) scientific teams and a highly productive NIH laboratory. Dr. Grammer received multiple awards for her team's work comparing genes expressed in patients compared with healthy individuals, including the prestigious NIH Director's Award as well as mentoring awards from the American Association of Immunologists. She has published over 75 articles on her scientific research.

Talk
RNA and Predictive AI Differentiate Benign from Malignant Tumors

Biography
Kathryn A. Phillips founded the UCSF Center for Translational and Policy Research on Precision Medicine over a decade ago. She has published 200 articles in major journals (e.g., JAMA, New England Journal of Medicine, Science, Health Affairs) and has had funding from NIH as a PI for 30 years. Kathryn is the EditorinChief of Health Affairs Scholar; serves on the editorial boards for Health Affairs, Value in Health, JAMA Internal Medicine; is a member of the National Academy of Medicine Roundtable on Genomics; has served on the Board of Directors for GenomeCanada and as an advisor to FDA and CDC; and is a member of ICERs evidence review committee.

Biography
Lincoln has over 8 years of experience in diagnostic development and a passion for translating genomic science into patient care. In his current role at Foundation Medicine he oversees evidence generation planning and execution for comprehensive genomic profiling assays with a focus on tissueagnostic monitoring. Lincoln most recently led the design and execution of the clinical strategy for a new ctDNA tumor fraction based on his deep scientific and disease biology understanding, translational expertise, and medical knowledge. Prior to joining Foundation Medicine, Lincoln worked at Caris Life Sciences and Health Advances, a boutique life sciences consulting firm, and holds an undergraduate degree in Biology from MIT and a PhD in microbiology and immunobiology from Harvard Medical School.

Biography
Dr. Hatim Husain is a boardcertified medical oncologist who specializes in lung cancer, genomicallyoriented targeted therapy, and immunotherapy. He is an Associate Professor at the University ofCalifornia, San Diego. Dr. Husain earned his medical degree from Northwestern University FeinbergSchool of Medicine. He completed a fellowship in medical oncology at Johns Hopkins University Schoolof Medicine and a residency in internal medicine at the University of Southern California. Dr. Husain is aphysicianscientist dedicated to understanding the cancer genome and tumor microenvironment andworks on strategies to advance meaningful, precisionoriented therapies for patients.